ModifiedBlue Cross Blue Shield - IowaPolicy N/A

Implantable Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

Covers use, medical necessity criteria, and investigational stance for implantable unilateral and bilateral hypoglossal nerve stimulation devices to treat obstructive sleep apnea in adults and select adolescents (Down syndrome). Affects providers submitting coverage requests to Blue Cross Blue Shield - Iowa/Wellmark.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyImplantable Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

Policy CodePolicy N/A

Change TypeClinical clarification and header revision

Effective DateMay 1, 2015

Next Review DateSep 1, 2025

Key ActionDocument prior CPAP failure or intolerance, baseline AHI/ODI and DISE findings when submitting prior authorization for HNS candidacy.

SourceLink

POLICY UPDATE CHANGES

BMI threshold for adults in medical necessity criteria appears as ≤35 kg/m2 in policy criteria though background/summaries reference prior thresholds of ≤32 or ≤35 in evidence discussion.

Policy revised February 2026 (document header shows revision).

2RCTs summarized

5 yrsDurable follow-up

15–65Adult AHI range

≤35Adult BMI threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

77%Treatment success (pooled)

CPT 64582,64583,64568Procedure codes listed

Coverage Criteria and Policy Stance

Implantable Unilateral Hypoglossal Nerve Stimulation — Adults

Covered when ALL of the following are met

Unilateral HNS (Adults): Age >= 18 years; AHI > 15 and < 65 with < 25% central apneas of total AHI; CPAP failure (residual AHI >= 15 or failure to use CPAP >= 4 hours/night for >= 5 nights/week) or inability to tolerate CPAP; Body mass index <= 35 kg/m2; Absence of complete concentric collapse at the soft palate level on drug-induced sleep endoscopy.see node text

Inspire® device referenced.

Implantable Unilateral Hypoglossal Nerve Stimulation — Adolescents (Down syndrome)

Covered when ALL of the following are met

Unilateral HNS (Adolescents with Down syndrome): Age 10 to 21 years; AHI >10 and <50 with < 25% central apneas after prior adenotonsillectomy; Have either tracheotomy or be ineffectively treated with CPAP due to noncompliance, discomfort, undesirable side effects, persistent symptoms despite compliant use, or refusal to use the device; Body mass index <= 95th percentile for age; Absence of complete concentric collapse at the soft palate level on DISE.see node text

Evidence limited; reported success ~73% in a prospective study of 42 individuals.

Implantable Bilateral Hypoglossal Nerve Stimulation — Policy stance

Policy stance

Bilateral HNS: Implantable bilateral hypoglossal nerve stimulation (Genio® System) is considered investigational because the evidence is insufficient to determine improvement in net health outcome.N/A

Only noncomparative single-arm data available; RCT evidence lacking.

Initial Therapy

Covered when ALL of the following are met

Device indication and patient selection: Patient has moderate-to-severe obstructive sleep apnea with AHI within device-specific labeling (examples: Inspire >15 and <100; Genio >=15 and <=65).AHI per device label

See device PMA/510(k) labeling for exact ranges

Prior therapy requirement: Patient has failed, cannot tolerate, or is ineligible for standard treatments including PAP, oral appliances, and other conservative measures.failed/intolerant PAP as described in device labeling

Documentation of PAP trial and intolerance required

Age and other device constraints: Patient meets age and BMI constraints per device labeling (e.g., adult age thresholds; Inspire expanded pediatric indication details described separately).

Clinical trial / registry eligibility

Common inclusion criteria used across RCTs and comparative studies

Typical trial inclusion: Adults with moderate-to-severe OSA (AHI thresholds vary by study, commonly AHI ≥ 15 to ≤ 65 or 20–65 events/hr), intolerant of CPAP, BMI typically ≤ 35 kg/m2 (some studies used ≤ 32 kg/m2), and favorable pattern of palatal collapse on drug-induced sleep endoscopy (non-concentric retropalatal collapse).AHI and BMI ranges as noted

Derived from multiple RCTs and observational cohorts

Evidence-derived coverage considerations

Evidence supports use in patients meeting trial-like selection criteria and demonstrating benefit on follow-up studies.

Typical trial-based inclusion: Patient has moderate-to-severe OSA with baseline AHI within ranges studied (e.g., STAR: >20 and <50 events/hr; other cohorts: >=15 and <=65), BMI within trial thresholds (STAR ≤ 32 kg/m2; some studies ≤ 35 kg/m2), intolerance or failure of CPAP, and a favorable pattern of palatal collapse on DISE.as stated

Derived from STAR trial and postmarket study inclusion criteria

Demonstrated post-implantation benefit: Follow-up polysomnography or validated outcome measures show clinically meaningful improvement (examples from studies: decrease in mean AHI from ~32 to ~14–15 at 12 months; responder rate per Sher criteria ~63–68%; registry mean AHI reduction and proportion achieving AHI <=5 reported).examples provided

Follow-up timing in studies varied (6–12 months typical); documentation of device use during testing noted as important

Initial coverage criteria — unilateral HNS

Covered when ALL of the following are met

Candidate selection: Patient has moderate-to-severe OSA and is intolerant of or failed PAP therapy.

Reference: multiple RCTs and registries included patients intolerant of CPAP.

Objective sleep testing: Baseline diagnostic polysomnography (PSG) or validated home sleep test documenting AHI and ODI prior to implantation.

Follow-up PSG or HST typically performed 2–12 months post-implant to document effect.

Anatomic consideration: Favorable pattern of palatal collapse (non-concentric retropalatal obstruction on DISE) or suitable anatomic evaluation by a sleep surgeon.

Success in studies associated with patient selection for collapse pattern.

BMI limits:

Coverage stance — bilateral HNS

Covered status for bilateral HNS

Evidence requirement: Bilateral implantable HNS currently supported only by noncomparative single-arm data; high-quality RCT evidence lacking.

Coverage may be conditional and require documentation of informed consent about limited comparative evidence.

Adult HNS initial therapy

Covered when ALL of the following are met:

Adult HNS candidacy: Age >=22 years; AHI 15-65 events/hr; central apnea index <25% of overall AHI; BMI <32; documented CPAP failure or intolerance; appropriate airway anatomy on drug-induced sleep endoscopy (DISE).see node text

Based on respondent synthesis and STAR/registry inclusion criteria

Pediatric (Down syndrome) HNS

Covered when ALL of the following are met (pediatric, Down syndrome context):

Pediatric HNS candidacy (Down syndrome): Age 10-21 years; prior adenotonsillectomy; BMI <95th percentile for age; severe OSA with AHI 10-50/hr and <25% central events; unable to tolerate CPAP or tracheostomy-dependent at night; need for future head MRI.see node text

From respondent summary of emerging pediatric evidence; study of 42 individuals reported ~73% success.

Coverage criteria — not specified in this section

no_coverage_criteria_provided: This section contains literature citations and commentary; it does not specify coverage decision logic or concrete inclusion/exclusion criteria.

See other policy parts for formal criteria.

Drug-induced sleep endoscopy (DISE) is used to evaluate the pattern of upper airway collapse and is required documentation for HNS candidacy. Presence of complete concentric collapse at the soft palate on DISE is an exclusion because concentric collapse is associated with decreased likelihood of HNS success and is specified as an exclusion by device labeling and policy guidelines.

Patients whose anatomic or physiologic findings do not match device-specific indications are excluded from HNS candidacy. Device labeling and regulatory summaries note that candidates must meet the AHI, age, and BMI ranges and exhibit appropriate airway collapse patterns (for example, nonconcentric palatal collapse) to be considered for implantation.

Many trials and registries excluded patients with concentric retropalatal obstruction on DISE (described as unfavorable palatal collapse). A favorable palatal pattern (non‑concentric retropalatal collapse) was commonly required for enrollment and is associated with higher likelihood of response to HNS.

Comparative studies and historical-control analyses have limited applicability to some patients because comparator procedures (e.g., UPPP or ESP) may not be appropriate for patients with primarily tongue‑base or lingual obstruction. Study populations and comparators were often dissimilar, which limits generalizability of comparative findings to all surgical candidates.

Evidence and major trials have largely enrolled patients with BMI ≤35 kg/m2 (and some pivotal trials used stricter cutoffs like ≤32 kg/m2). Patients with BMI >35 kg/m2 are underrepresented in the evidence base and guideline recommendations emphasize weight‑loss strategies or bariatric referral in class II/III obesity rather than routine HNS.

The National Institute for Health and Clinical Excellence (NICE) concluded that evidence on HNS was limited in quantity and quality and recommended that HNS only be used with special arrangements for governance, consent, and audit, implying restricted use settings and additional oversight rather than routine adoption.

Respondent input summarized in the review indicated that individuals with mild OSA who have failed CPAP were generally not viewed as appropriate candidates for HNS; respondents repeatedly answered 'No' when asked whether HNS provides clinically meaningful improvement for mild OSA.

Within the excerpted discussion there are no additional explicit exclusion conditions beyond those stated elsewhere. The narrative does reference pediatric reports and special‑population discussions but does not define new, separate exclusions in this section.

When the published criteria are not met, implantable unilateral HNS is considered investigational. The bilateral Genio® system is explicitly considered investigational in this policy because high‑quality evidence demonstrating net health benefit is lacking.

Use of HNS for indications not supported by the published evidence or device labeling — for example, patients without documented CPAP failure/intolerance or those outside labeled AHI, age, or BMI ranges — is not supported by the evidence base and therefore not considered appropriate per the document's evidence summaries.

Direct comparative evidence of HNS versus other airway surgeries is limited. A small number of observational studies compared HNS to historical controls treated with UPPP or variants, but differences in patient selection (notably palatal collapse pattern and prior procedures) reduce confidence in direct comparisons.

Many comparative studies were nonrandomized, retrospective, and lacked blinding or adequate control for selection bias. These study design and conduct limitations constrain interpretation of comparative effectiveness and increase uncertainty about how well results generalize to broader clinical populations.

Given the limited evidence base for bilateral HNS (no published RCTs and mainly single‑arm data), a payer may reasonably consider bilateral HNS not medically necessary or restrict coverage to research or audit settings until higher‑quality comparative evidence is available.

Respondents and single‑arm pediatric reports indicated mixed views on HNS for mild OSA; in the survey responses clinicians generally did not endorse HNS for mild disease, whereas small pediatric Down syndrome series reported favorable responder rates in highly selected patients.

This section of the document contains narrative citations and commentary and does not itself include explicit 'not medically necessary' declarations; where NMN stances are stated elsewhere they are tied to evidence gaps or off‑label use.

Codes, Indications, and Key Numeric Criteria

Device regulatory identifiersmixed

P130008, S039, S089, S090, S098

PMA/510(k) identifiers for Inspire unilateral hypoglossal nerve stimulation system as listed in regulatory table

Regulatory PMA/510(k) identifiers referencedmixed

P130008	Inspire® PMA/510(k)
P240024	Genio® Bilateral HNS PMA
S039	510(k) predicate
S089	510(k) predicate
S090	510(k) predicate
S098	510(k) predicate

Codes referenced in this excerptmixed

No codes listed

Procedure CPT CodesCPT

64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respirator sensor electrode or electrode array.
64583	Revision or implantation of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator.
64999	Unlisted procedure, nervous system.

Programming/Analysis CPT CodesCPT

95970	Electronic analysis of implanted neurostimulation pulse generator system/transmitter without programming.
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple cranial nerve neurostimulator programming.
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter with complex cranial nerve neurostimulator programming.

HCPCS / C-codes / L-codes (Device supplies)HCPCS

C1767	Generator neurostimulator (implantable) non-rechargeable.
C1778	Lead, neurostimulator.
C1787	Patient programmer, neurostimulator.
C1816	Receiver and/or transmitter neurostimulator (implantable).
C1820	Generator, neurostimulator (implantable), non-high frequency with rechargeable battery and charging system.
C1822	Generator, neurostimulator (implantable), high frequency with rechargeable battery and charging system.
C1883	Adapter/extension, pacing lead or neurostimulator lead (implantable).
C1897	Lead neurostimulator test kit (implantable).
L8679	Implantable neurostimulator pulse generator any type.
L8680	Implantable neurostimulator electrode, each.

1–10 of 12

1/2

AHI — adults and adolescents AHI thresholds

Adult AHI (policy)AHI >15 and <65 events/hour (adults)

Adolescent (Down syndrome) AHIAHI >10 and <50 events/hour (age 10–21 yrs)

Device-label examplesInspire: >15 (lower) with upper limits per labeling; Genio examples noted separately

Central apnea proportion — threshold

Central apnea proportion thresholdCentral apneas <25% of total AHI (central apnea index <25% of overall AHI)

Prior Authorization, Documentation, and Operational Steps

Prior Authorization

Prior Authorization: Clinical Qualification

Prior authorization: Clinical qualification — Prior authorization is expected for implantable hypoglossal nerve stimulation (HNS). Document moderate-to-severe OSA and prior conservative therapy failure/intolerance (CPAP failure or inability to tolerate CPAP). Confirm age and indication-specific AHI ranges and percent central apneas, BMI threshold, and DISE findings per device indication.

Age: adults ≥18 years (special pediatric/Down syndrome criteria apply: age 10–21 for adolescents/young adults with Down syndrome)
AHI: typically >15 (or >10 for pediatric Down syndrome cohort) and upper trial-specific bounds (commonly <65 in adults, <50 in pediatric Down syndrome) with <25% central apneas
CPAP failure/intolerance: prior adequate CPAP trial with residual AHI ≥15 or inability/unwillingness to use CPAP (commonly defined as <4 hours/night on ≥5 nights/week)
BMI: adults generally ≤35 kg/m2 for many studies; pivotal/STAR guidance often uses BMI ≤32 kg/m2 as optimal selection
DISE: absence of complete concentric collapse at the soft palate on drug-induced sleep endoscopy is required

Clinical Background and Evidence Context

Obstructive sleep apnea (OSA) is characterized by recurrent upper‑airway collapse during sleep producing apneas and hypopneas that increase daytime sleepiness and cardiopulmonary risk. Hypoglossal nerve stimulation (HNS) activates the genioglossus via cranial nerve XII to advance and stiffen the tongue, reducing airway collapsibility and improving airflow at the soft palate and tongue‑base levels.

Definitions and Outcome Measures

AHI; CPAP failure/intolerance — definitions and context

AHI and CPAP failure/intolerance definitionAHI: average number of apneas/hypopneas per hour; CPAP failure = residual AHI ≥15 while using PAP OR CPAP use <4 h/night for ≥5 nights/week (intolerance)

Clinical relevancePolicy requires documentation of CPAP failure or intolerance as prerequisite for HNS candidacy

Source/testConfirm via PSG reports and CPAP adherence data prior to authorization

DISE / concentric collapse — DISE definition and relevance

DISE definitionDrug-induced sleep endoscopy (DISE) replicates sleep using propofol to evaluate pharyngeal collapse patterns

Concentric collapse relevanceComplete concentric (circumferential) oropharyngeal collapse at the soft palate decreases HNS success and is an exclusion

Policy Revision History

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyImplantable Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

Policy CodePolicy N/A

Change TypeClinical clarification and header revision

Effective DateMay 1, 2015

Next Review DateSep 1, 2025

Key ActionDocument prior CPAP failure or intolerance, baseline AHI/ODI and DISE findings when submitting prior authorization for HNS candidacy.

SourceLink

On This Page

age and BMI per labeling

Refer to specific device indications (Inspire, Genio) for age/BMI criteria

BMI within ranges studied (most evidence in patients with BMI ≤ 35 kg/m2; many pivotal studies used BMI ≤ 32 kg/m2).

Evidence shows decreasing odds of response with increasing BMI; some registries limited enrollment to <=35 kg/m2.

Used as an exclusion for HNS candidacy in device labeling and policy

DocumentationReport central apnea proportion from diagnostic PSG to confirm <25%

Adult BMI — numeric threshold

Adult BMI (policy criterion)Body mass index ≤35 kg/m2 (policy medical necessity criterion)

BMI and evidenceMost trials/registries enrolled patients with BMI ≤35 kg/m2; STAR used ≤32 kg/m2

Registry observationsADHERE analyses show better outcomes at lower BMI and note reduced odds of response with higher BMI

Adolescent BMI — percentile threshold

Adolescent BMI thresholdBody mass index ≤95th percentile for age (pediatric Down syndrome criterion)

Age range contextApplies to adolescents/young adults 10–21 years with Down syndrome in policy criteria

Prior surgery requirementApplied after prior adenotonsillectomy per pediatric criteria

AHI indication range (Genio®)

Genio® AHI indication range>=15 and <=65 events/hour (Genio bilateral HNS labeling example)

Intended populationAdults with moderate-to-severe OSA meeting device-specific labeling (see PMA)

Regulatory referenceGenio PMA referenced in regulatory table (P240024)

AHI indication range (Inspire®)

Inspire® AHI indication range>15 and <100 events/hour per Inspire device labeling (regulatory table)

FDA-approved predicateInspire Upper Airway Stimulation System indicated for patients >18 yrs with AHI >15 (labeling specifies upper limit)

Label evolutionInspire labeling includes adult and expanded pediatric (Down syndrome) indications under post-approval requirements

BMI upper limit (expanded for Inspire) — historical labeling differences

Historical BMI upper limitsEarlier Inspire references cited BMI upper limit <32 kg/m2; later documents note expanded upper limits reported (eg, <40 kg/m2 in some summaries)

Regulatory/label notesPolicy and regulatory summaries describe prior and updated BMI language across device materials

Evidence vs labelingTrials often used stricter BMI cutoffs (≤32 or ≤35) despite some labeling expansions

AHI eligibility ranges used in trials — trial-specific ranges summary

Common trial AHI rangesMany trials enrolled patients with AHI in the 15–65 events/hr range; some trials used 20–65 or >15 depending on study (e.g., THN3: 20–65; EFFECT: >15)

STAR trial rangeSTAR enrolled patients with AHI >20 and <50 events/hr

Trial variabilityAHI inclusion criteria varied by device and study; refer to individual trial tables for specifics

BMI thresholds used in trials — trial enrollment BMI cutoffs

Trial BMI cutoffsMany trials enrolled patients with BMI ≤35 kg/m2; STAR used BMI ≤32 kg/m2 as an eligibility cutoff

THN3 and postmarketTHN3 and several postmarket studies limited enrollment to BMI ≤35 kg/m2

Registry enrollmentADHERE registry included patients up to BMI 35 kg/m2 in reporting and analyses

BMI threshold — STAR trial vs other studies

STAR vs other BMI thresholdsSTAR trial used BMI ≤32 kg/m2; many postmarket/registry studies and later trials enrolled patients with BMI ≤35 kg/m2

Impact of BMI on outcomesRegistry analyses report decreasing odds of response with increasing BMI; lower BMI associated with higher success

Practical guidanceBMI ≤32 often used as favorable selection criterion though evidence supports some benefit up to BMI ≤35

AHI eligibility ranges in key studies — STAR and others

STAR trial AHI eligibilitySTAR: AHI >20 and <50 events/hour

Other key study rangesOther cohorts and RCTs used AHI ≥15 to ≤65 or study-specific ranges (eg, THN3: 20–65; EFFECT: >15)

Outcome baselinesMany single-arm cohorts had baseline mean AHI ~31–32 events/hour

Body mass index (BMI) — policy numeric summary

Policy BMI summaryPolicy numeric summary: adults — BMI thresholds referenced include ≤35 kg/m2 (policy) and favorable BMI ≤32 kg/m2 used in some trials

Registry/trial noteMost trial evidence and registries enrolled patients with BMI ≤35 kg/m2; STAR used ≤32 kg/m2

Clinical implicationHigher BMI is associated with lower odds of response; document BMI when seeking authorization

AHI — adults and pediatric Down syndrome adolescents

AHI for adults and pediatric Down syndrome adolescentsAdults: AHI >15 and <65 events/hr; Adolescents with Down syndrome (age 10–21): AHI >10 and <50 events/hr

Central apnea constraintBoth groups require central apneas <25% of total AHI

Prior surgery/therapy for pediatricsPediatric Down syndrome candidates typically require prior adenotonsillectomy before HNS consideration

BMI — adult and pediatric numeric guidance

BMI guidance (adult and pediatric)Adults: policy lists BMI ≤35 kg/m2 (with many references favoring ≤32 kg/m2); Pediatrics (Down syndrome): BMI ≤95th percentile for age

Documentation needRecord and report BMI or percentile on prior testing and prior to authorization

Evidence noteTrials and registries predominantly enrolled BMI ≤35 kg/m2; STAR used ≤32 kg/m2

Central apnea index — threshold

Central apnea index thresholdCentral apnea index (central apneas) should be <25% of overall AHI to qualify

MeasurementConfirm from diagnostic PSG reporting central apnea proportion to verify <25%

Exclusion rationaleHigher central apnea proportion reduces likelihood of benefit and is an exclusion in labeling/policy

Age — adult and pediatric age ranges referenced

Age ranges referencedAdults: policy criteria cite age ≥18 years for unilateral HNS and some references note CMS criteria ≥22 years; Pediatrics: 10–21 years for Down syndrome adolescents

Device-specific age notesInspire labeling and CMS guidance reference adult thresholds; expanded pediatric/young-adult indications are noted for Down syndrome populations

Authorization implicationConfirm patient age falls within device labeling or policy-specified age range before approval

Prior Authorization Influences Registry Cohorts

Prior authorization influences registry cohorts — Insurance approval decisions affect registry comparator groups and may bias observational comparisons; registry reports noted that patients denied coverage formed a non-treated comparator group. Prior authorization criteria (eg, prior PAP use, prior surgeries) were predictors of approval in registry analyses and can affect who enters registries vs denied cohorts.

ADHERE registry analyses compared treated patients to those denied coverage; prior PAP use and prior surgeries predicted approval (Mehra et al, 2020)
Denial-driven comparator groups may have lower treatment engagement and different follow-up testing (eg, lower use, more home sleep tests) — consider potential bias when reviewing registry outcomes

Billing Rule

Prior Authorization and Coding

Prior authorization and coding — When seeking authorization, include the CPT/HCPCS/L-code and programming/service codes that will be billed. Supply documentation supporting the planned CPT/HCPCS codes (implantation, revisions, device components) and any anticipated programming/analysis services.

Common CPT codes: 64568 (open implantation cranial nerve neurostimulator array/pulse generator), 64582 (implantation of hypoglossal nerve neurostimulator array/pulse generator and distal sensor), 64583 (revision/implantation including connection to existing generator), 64999 (unlisted procedure)
Programming/analysis CPT: 95970 (electronic analysis without programming), 95976 (analysis with simple cranial nerve programming), 95977 (analysis with complex cranial nerve programming)
HCPCS/L-codes: C1767, C1778, C1787, C1816, C1820, C1822, C1883, C1897, L8679, L8680, L8681 — include expected device descriptors and L-codes where applicable

Note

Prior Authorization: Literature–Focused Context

Prior authorization: Literature-focused — The policy bases medical necessity on the published evidence and registry data rather than an exhaustive code list. Authorization decisions should reference pivotal trials (STAR, RCTs, registry publications) and post‑approval study requirements for expanded indications (eg, adolescent Down syndrome registry).

Key evidence sources: STAR pivotal study and follow-ups, randomized trials (eg, THN3, EFFECT), ADHERE registry publications and post‑approval registry designs
Expanded/younger-age approvals are contingent on post‑approval registries and longitudinal follow-up visits (pre‑implant, post‑implant, 6 months, then yearly up to 5 years)

Denial Risk

Denial Triggers

Denial triggers — Applications missing ANY required medical necessity criteria are at high risk of denial. Common denial triggers include failure to document age/indication alignment, inadequate CPAP trial documentation, out-of-range AHI/central apnea percentage, BMI above device/trial thresholds, or DISE showing concentric soft-palate collapse.

Lack of documentation of ALL medical necessity criteria (age, AHI, central apnea %, CPAP failure/intolerance, BMI, DISE findings)
DISE showing complete concentric collapse at the soft palate is an exclusion and will trigger denial
Patients outside device indication ranges (eg, AHI or BMI beyond trial/device limits) commonly denied

Denial Risk

Indication Mismatch Risk

Indication mismatch — Individuals outside the labeled or trial-supported indications (age, AHI range, central apnea fraction, BMI, DISE pattern) are often considered not appropriate for HNS and may be denied. Explicitly note when a patient falls outside a device-specific indication window.

Adult indication bounds (typical adult criteria): AHI >15 to <65; <25% central events; BMI thresholds vary (STAR often ≤32, other studies ≤35)
Pediatric/Down syndrome cohort has distinct age and AHI/BMI thresholds (eg, age 10–21, AHI >10 to <50, BMI ≤95th percentile)
When indication differs from the device’s FDA label or key trial inclusion criteria, explain rationale and cite supporting evidence if requesting exception

Note

Insurance Approval Predictors (Registry Findings)

Insurance approval predictors noted in registry analysis — Registry analyses identified factors associated with insurance approval; include these data when assembling prior authorization packages to illustrate prior PAP use or prior surgical history where present.

Mehra et al (ADHERE): previous PAP use and prior surgeries were predictors of insurance approval
Document prior conservative therapy utilization and prior OSA surgeries when present to align with factors associated with approval

Denial Risk

Eligibility‑Related Denial Risk

Eligibility-related denial risk — Patients who do not meet STAR or other trial eligibility criteria (eg, BMI above cutoffs, unfavorable palatal collapse pattern) have greater denial risk. If an applicant’s characteristics differ, provide supporting data or rationale for exception.

BMI >32–35 kg/m2 increases denial risk; some studies include select higher‑BMI patients but require specific anatomic considerations
Unfavorable palatal collapse (complete concentric collapse) on DISE raises the risk of noncoverage
Describe any selection-based exceptions (eg, favorable cervical landmarks) and supply institutional data if available

Note

Regulatory and Coverage Caution

Regulatory/coverage caution — National guidance (eg, NICE) recommends special arrangements for governance, consent, and audit when using HNS; expanded indications may be contingent on post‑approval studies/registries. Consider governance and documentation plans when submitting prior authorization.

NICE IPG598 (2017): recommends use only with arrangements for clinical governance, consent, and audit
FDA expanded pediatric indications are contingent on post‑approval registry enrollment and scheduled follow‑up through multi‑year intervals

Note

No Single Authorization/Denial Trigger — Operational Note

No explicit authorization or denial triggers — The policy does not enumerate a separate checklist or single automated trigger list; decisions are based on meeting ALL medical necessity criteria and the supporting evidence. Provide full supporting documentation rather than relying on code-only submission.

Prior approval section: Not applicable (policy states prior approval not applicable) but clinical criteria and documentation expectations drive coverage decisions
There is no single automated authorization/denial flag — reviewers assess documentation against clinical criteria and evidence

Documentation Required

Required Clinical Documentation Elements

Required clinical documentation elements (as used in trials) — Submit diagnostic sleep study data, prior CPAP therapy details, DISE findings, BMI/anthropometrics, and patient-reported outcomes where available. Include documentation of trial-specific thresholds (AHI, central apnea %, BMI) and prior treatments.

Baseline diagnostic PSG or validated HST with reported AHI and ODI (include date and methodology)
Documentation of prior CPAP trial: duration, adherence data (hours/night and nights/week), residual AHI on PAP, or documented intolerance/failure
DISE report documenting absence of complete concentric collapse at the soft palate (video or detailed operative note preferred)
Anthropometrics: BMI (or percentile for pediatric patients) with date
Patient-reported outcomes: ESS, FOSQ, OSA-18 (for pediatric/Down syndrome) when available

Documentation Required

Sleep Study and Outcomes Documentation

Sleep study and outcomes documentation — Provide baseline and post‑implantation sleep testing (PSG or home sleep test) results and device use/titration PSG details. Registry and trial follow-up schedules (eg, 2–6 months, 6 months, 12 months, then yearly) are commonly used.

Pre‑implant PSG/HST with AHI, ODI, oxygen nadir, and central apnea percentage
Post‑implant titration PSG and follow‑up sleep testing (commonly at 2–6 months, 6 and 12 months, then yearly) with device usage on test nights when available
Report objective device usage data (hours/night, hours/week) downloaded from the device to support effectiveness and adherence claims

Note

No Standardized Authorization Checklist Provided

No documentation checklist or required form specified — The policy does not provide a standardized prior authorization checklist or form; include the clinical elements listed above and cite applicable trials/registry evidence when requesting coverage.

Policy lacks a mandated authorization checklist or submission form — assemble a clear narrative and attach PSG/HST reports, CPAP adherence data, DISE report, BMI, and relevant clinical notes
If requesting an exception to typical inclusion criteria, include peer‑reviewed evidence or institutional outcome data to support the request

Step Therapy

CPAP Intolerance as a Common Precondition in Trials

CPAP intolerance as common precondition in trials — Most RCTs and prospective cohorts enrolled patients who were intolerant of or had failed CPAP; prior CPAP failure/intolerance is a consistent prerequisite for HNS candidacy in the evidence base.

Trials (STAR, THN3, EFFECT) and registries commonly required failed or intolerant CPAP as an entry criterion
When prior CPAP trial data are unavailable, document reasons for intolerance and any objective adherence data if possible

Step Therapy

Pediatric Treatment Sequencing

Pediatric treatment sequencing — For pediatric patients (particularly with adenotonsillar hypertrophy), adenotonsillectomy is first‑line; CPAP is recommended when appropriate. HNS for adolescents with Down syndrome is considered after adenotonsillectomy and when CPAP is not tolerated.

AAP guidance: adenotonsillectomy is first‑line for children with adenotonsillar hypertrophy and OSA
HNS in adolescents with Down syndrome: age 10–21, prior adenotonsillectomy, AHI and central apnea thresholds, and inability to tolerate CPAP or tracheostomy dependence

Step Therapy

Step‑Therapy / Sequencing Note

No step therapy requirements or sequencing mandated in policy — While CPAP is the preferred first‑line treatment and trials required prior CPAP failure/intolerance, the policy does not impose an explicit step‑therapy algorithm or mandatory duration beyond documenting prior adequate CPAP trial or intolerance.

CPAP is preferred first‑line therapy; HNS is intended for patients who have failed or cannot tolerate CPAP
Policy does not define a single mandatory step‑therapy pathway or fixed CPAP duration beyond documentation of prior trial/failure

Selection useDISE used to document favorable non-concentric retropalatal obstruction for candidate selection

AHI — device indication thresholds referenced

Device AHI thresholds referencedInspire labeling: AHI >15 with upper limit per labeling (policy cites >15 and <100); Genio labeling: >=15 and <=65

Policy vs device labelsPolicy aligns candidacy with device-specific AHI ranges and trial inclusion criteria

Confirm labelsRefer to device PMA/510(k) documentation for exact labeled ranges when evaluating candidacy

Genio system components — activation chip and disposable patch

Genio system componentsImplantable stimulator (IS) plus external activation chip (AC) attached to a disposable adhesive patch (DP) transmitting energy pulses to the IS

External controlAC transmits stimulation during therapy via adhesive patch placed under the chin; programming uses Sleep Lab Application and smartphone app

IS characteristicsIS has no battery/software; receives rectified square-wave pulses to stimulate hypoglossal nerve terminals bilaterally

Surgical success (Sher criteria) — responder definition

Sher criteria (surgical success)Responder defined as ≥50% reduction in AHI and final AHI <20 (Sher criteria)

Usage in studiesMany trials and registries report responder rates using Sher criteria (eg, registry pooled success ~77%)

Alternate thresholdsStudies also report AHI <5, <10, or <15 as alternative success endpoints

Favorable pattern of palatal collapse — non-concentric retropalatal obstruction

Favorable palatal collapse patternNon-concentric (non-circumferential) retropalatal obstruction on DISE is considered a favorable pattern

Selection roleMany trials (eg, STAR) required non-concentric retropalatal collapse for enrollment

Unfavorable patternConcentric retropalatal collapse is associated with decreased likelihood of HNS success and is exclusionary

Sher criteria — responder definition (≥50% reduction and AHI <20)

Sher criteria restatedResponder definition: at least 50% decrease in AHI and final AHI <20 (Sher criteria)

Clinical reportingUsed widely as primary success endpoint in single-arm and registry studies

Associated metricsOften reported alongside mean AHI reduction, ODI, and ESS improvements

Favorable pattern of palatal collapse (STAR trial) — non-concentric retropalatal obstruction

STAR trial palatal collapse requirementSTAR trial required non-concentric retropalatal obstruction on DISE (favorable palatal collapse)

Selection implicationFavorable collapse pattern was a key enrollment criterion linked to response rates

DISE roleDISE used to screen for palatal collapse pattern pre-implantation

AHI (Apnea/Hypopnea Index) — outcome measure definition

AHI definitionApnea–Hypopnea Index (AHI): average number of apneas and hypopneas per hour of sleep

Measurement contextComputed from PSG channels assessing airflow, effort, and oxygen desaturation; used as primary efficacy outcome

Clinical thresholdsSeverity categories: mild (AHI 5–<15), moderate (15–<30), severe (≥30) in adults

ODI (Oxygen Desaturation Index) — outcome measure definition

ODI definitionOxygen Desaturation Index (ODI): number of times per hour blood oxygen drops by ≥4 percentage points

Clinical meaningClinically meaningful differences often defined as >5 events/hour

Usage in studiesODI reported alongside AHI to assess physiologic improvement post-HNS

ESS (Epworth Sleepiness Scale) — patient-reported outcome definition and MCID

ESS definitionEpworth Sleepiness Scale (ESS): 0–24 patient-reported daytime sleepiness scale; ESS ≥10 indicates excessive sleepiness

MCIDMinimum clinically important difference estimated at −2 to −3 points

Study useCommon patient-reported outcome in HNS trials and registries to document symptomatic improvement

Implantation procedures — CPT codes and procedure descriptions

Relevant CPT codes (implantation)CPT 64568, 64582, 64583, 64999 listed for implantation and related procedures

Programming/analysis CPTsCPT 95970, 95976, 95977 for electronic analysis/programming of implanted neurostimulators

DocumentationReport services using appropriate CPTs and HCPCS/L-codes as listed in policy when submitting claims

HNS/UAS — terminology

TerminologyHNS = Hypoglossal Nerve Stimulation; UAS = Upper Airway Stimulation (used interchangeably)

DevicesUnilateral HNS (eg, Inspire) and bilateral HNS (eg, Genio) are forms of UAS/HNS

Clinical usageTerm used across trials, registries, and device labeling in the policy

Effective AHI — comparator methodology note

Effective AHI noteEffective AHI is a comparator methodology accounting for PAP adherence when comparing outcomes between PAP and HNS

Comparative contextUsed in analyses comparing HNS to PAP where adherence influences apparent effectiveness

ImplicationConsider adherence-adjusted measures when evaluating comparative effectiveness

STAR trial — pivotal trial reference

STAR trial identificationSTAR trial: pivotal single-arm trial of upper-airway stimulation with long-term follow-up (5 years) used as key reference

STAR enrollmentEnrolled patients with AHI >20 and <50 and BMI ≤32 kg/m2 with favorable palatal collapse

Role in evidence baseSTAR provides durable outcomes frequently cited in policy and guidance

ADHERE registry — registry reference

ADHERE registry referenceADHERE registry: multicenter registry reporting real-world outcomes, pooled in analyses (eg, Kent et al 2019; Boon et al 2018)

Registry findingsRegistry reports treatment success rates (eg, 77% by Sher criteria) and mean AHI reductions in larger cohorts

Influence on policyRegistry evidence supplements trial data for real-world effectiveness and selection factors